Expression of p-STAT3 in human gastric carcinoma: Significant correlation in tumour invasion and prognosis

International Journal of Oncology

Volumn 30, Issue 2, 2007, Pages 437-442

  Yakata, Yuichi ^a   Nakayama, Toshiyuki ^a   Yoshizaki, Ayumi ^a   Kusaba, Takafumi ^a   Inoue, Kenichiro ^b   Sekine, Ichiro ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b Shunkaikai Inoue Hospital   (Japan)

Author keywords

Gastric cancer; Immunohistochemistry; Invasion; Phosphorylated STAT3; Prognosis

Indexed keywords

STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADENOMA; ADULT; AGED; ARTICLE; BIOSYNTHESIS; CANCER INVASION; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PROGNOSIS; STOMACH TUMOR;

ADENOCARCINOMA; ADENOMA; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS;

EID: 34047259844     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Neugut AI, Hayek M and Howe G: Epidemiology of gastric cancer. Semin Oncol 23: 281-291, 1996.
2. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1988.
3. Ming SC and Goldman H: Pathology of the gastrointestinal tract. 2nd edition. Williams & Wilkins, Baltimore, pp632-633, 1998.
4. Goseki N, Koike M and Yoshida M: Histopathologic characteristics of early stage esophageal carcinoma. A comparative study with gastric carcinoma. Cancer 69: 1088-1093, 1992.
5. Darnell JE Jr: STATs and gene regulation. Science 277: 1630-1635, 1997.
6. Bromberg J: Stat proteins and oncogenesis. J Clin Invest 109: 1139-1142, 2002.
7. Levy DE and Darnell JE Jr: Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662, 2000.
8. Smithgall TE, Briggs SD, Schreiner S, Lerner EC, Cheng H and Wilson MB: Control of myeloid differentiation and survival by Stats. Oncogene 19: 2612-2618, 2000.
9. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J and Jove R: Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62: 6659-6666, 2002.
10. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS and Jove R: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115, 1999.
11. Spiekermann K, Biethahn S, Wilde S, Hiddemann W and Alves F: Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol 67: 63-71, 2001. (Pubitemid 33010380)
12. Dhir R, Ni Z, Lou W, Demiguel F, Grandis JR and Gao AC: Stat3 activation in prostatic carcinomas. Prostate 51: 241-246, 2002.
13. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y and Kim JD: Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 97: 4227-4232, 2000.
14. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T and Sekine I: Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol 58: 833-838, 2005.
15. Feng DY, Zheng H, Tan Y and Cheng RX: Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance. World J Gastroenterol 7: 33-36, 2001. (Pubitemid 32170895)
16. Bromberg JF, Horvath CM, Besser D, Lathem WW and Darnell JE Jr: Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 18: 2553-2558, 1998. (Pubitemid 28183425)
17. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Coutneidge SA and Jove R: Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 98: 7319-7324, 2001. (Pubitemid 32567946)
18. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an oncogene. Cell 98: 295-303, 1999.
19. Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene 19: 2474-2488, 2000.
20. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM and Fernandez-Luna JL: Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21: 7611-7618, 2002.
21. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S and Weinstein IB: Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 62: 3351-3315, 2002.
22. Huang M, Page C, Reynolds RK and Lin J: Constitutive activation of stat3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol 79: 67-73, 2000.
23. Bartoli M, Gu X, Tsai NT, Venema RC, Brooks SE, Marrero MB and Caldwell RB: Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J Biol Chem 275: 33189-33192, 2000.
24. Campbell CL, Jiang Z, Savarese DM and Savarese TM: Increased expression of the interleukin-11 receptor and evidence of Stat3 activation in prostate carcinoma. Am J Pathol 158: 25-32, 2001.
25. Nishi M, Omori Y and Miwa K (eds): Japanese Classification of Gastric Carcinoma, Japanese Research Society for Gastric Cancer. English edition. Kanehara & Co., Ltd., Tokyo, 1995.
26. Seefeld PH and Bargen JA: The spread of cancer of the rectum: invasion of the lymphatic, veins and nerves. Ann Surg 118: 76-89, 1943.
27. Talbot IC, Ritchie S, Leighton M, Hughes AO, Bussey HJ and Morson BC: Invasion of veins by carcinoma of rectum: methods of detection, histological features and significance. Histopathology 5: 141-163, 1981.
28. Darnell JE Jr, Kerr IM and Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421, 1994.
29. Burke WM, Jin X, Lin HJ, Huang M, Liu R, Reynolds RK and Lin J: Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 20: 7925-7934, 2001. (Pubitemid 34002969)
30. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA and Haque SJ: Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21: 8404-8413, 2002.
31. Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y, Sekikawa A, Kawada M, Suzuki K, Kayahara T, Fukui H, Sawada M and Chiba T: STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 23: 4921-4929, 2004.
32. Ma XT, Wang S, Ye YJ, Du RY, Cui ZR and Somsouk M: Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World J Gastroenterol 10: 1569-1573, 2004.
33. Giri D, Ozen M and Ittmann M: Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159: 2159-2165, 2001. (Pubitemid 33104270)
34. Bisping G, Leo R, Wenning D, Dankbar B, Padro T, Kropff M, Scheffold C, Kroger M, Mesters RM, Berdel WE and Kienast J: Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 101: 2775-2783, 2003.
35. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR and Dvorak HF: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53: 4727-4735, 1993. (Pubitemid 23304407)
36. Sier CF, Kuben FJ, Ganesh S, Heerding MM, Griffionen G, Hanemaaijer R, van Krieken JH, Lamers CB and Verspaget HW: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 74: 413-417, 1996.
37. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, Nagayasu T and Sekine I: Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 15: 1445-1451, 2006.
38. Rivat C, De Wever O, Bruyneel E, Mareel M, Gespach C and Attoub S: Disruption of STAT3 signaling leads to tumor cell invasion through alterations of homotypic cell-cell adhesion complexes. Oncogene 23: 3317-3327, 2004.
39. Berclaz G, Altermatt HJ, Rohrbach V, Siragusa A, Dreher E and Smith PD: EGFR dependent expression of Stat3 (but not STAT1) in breast cancer. Int J Oncol 19: 1155-1160, 2001.
40. Xia Z, Sait SN, Baer MR, Barcos M, Donohue KA, Lawrence D, Ford LA, Block AM, Baumann H and Wetzler M: Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. Leuk Res 25: 473-482, 2001.
41. Werner M, Becker KF, Keller G and Hofler H: Gastric adenocarcinoma: pathomorphology and molecular pathology. J Cancer Res Clin Oncol 127: 207-216, 2001.